IBDEI0SM ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12880,0)
 ;;=H34.8321^^51^623^8
 ;;^UTILITY(U,$J,358.3,12880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12880,1,3,0)
 ;;=3^BRVO,OS w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,12880,1,4,0)
 ;;=4^H34.8321
 ;;^UTILITY(U,$J,358.3,12880,2)
 ;;=^5138492
 ;;^UTILITY(U,$J,358.3,12881,0)
 ;;=H34.8322^^51^623^9
 ;;^UTILITY(U,$J,358.3,12881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12881,1,3,0)
 ;;=3^BRVO,OS,Stable
 ;;^UTILITY(U,$J,358.3,12881,1,4,0)
 ;;=4^H34.8322
 ;;^UTILITY(U,$J,358.3,12881,2)
 ;;=^5138493
 ;;^UTILITY(U,$J,358.3,12882,0)
 ;;=H34.8110^^51^623^10
 ;;^UTILITY(U,$J,358.3,12882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12882,1,3,0)
 ;;=3^CRVO,OD w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,12882,1,4,0)
 ;;=4^H34.8110
 ;;^UTILITY(U,$J,358.3,12882,2)
 ;;=^5138476
 ;;^UTILITY(U,$J,358.3,12883,0)
 ;;=H34.8111^^51^623^11
 ;;^UTILITY(U,$J,358.3,12883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12883,1,3,0)
 ;;=3^CRVO,OD w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,12883,1,4,0)
 ;;=4^H34.8111
 ;;^UTILITY(U,$J,358.3,12883,2)
 ;;=^5138477
 ;;^UTILITY(U,$J,358.3,12884,0)
 ;;=H34.8112^^51^623^12
 ;;^UTILITY(U,$J,358.3,12884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12884,1,3,0)
 ;;=3^CRVO,OD,Stable
 ;;^UTILITY(U,$J,358.3,12884,1,4,0)
 ;;=4^H34.8112
 ;;^UTILITY(U,$J,358.3,12884,2)
 ;;=^5138478
 ;;^UTILITY(U,$J,358.3,12885,0)
 ;;=H34.8120^^51^623^13
 ;;^UTILITY(U,$J,358.3,12885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12885,1,3,0)
 ;;=3^CRVO,OS w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,12885,1,4,0)
 ;;=4^H34.8120
 ;;^UTILITY(U,$J,358.3,12885,2)
 ;;=^5138479
 ;;^UTILITY(U,$J,358.3,12886,0)
 ;;=H34.8121^^51^623^14
 ;;^UTILITY(U,$J,358.3,12886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12886,1,3,0)
 ;;=3^CRVO,OS w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,12886,1,4,0)
 ;;=4^H34.8121
 ;;^UTILITY(U,$J,358.3,12886,2)
 ;;=^5138480
 ;;^UTILITY(U,$J,358.3,12887,0)
 ;;=H34.8122^^51^623^15
 ;;^UTILITY(U,$J,358.3,12887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12887,1,3,0)
 ;;=3^CRVO,OS,Stable
 ;;^UTILITY(U,$J,358.3,12887,1,4,0)
 ;;=4^H34.8122
 ;;^UTILITY(U,$J,358.3,12887,2)
 ;;=^5138481
 ;;^UTILITY(U,$J,358.3,12888,0)
 ;;=H35.013^^51^623^40
 ;;^UTILITY(U,$J,358.3,12888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12888,1,3,0)
 ;;=3^Changes in Retinal Vascular Appearance,OU
 ;;^UTILITY(U,$J,358.3,12888,1,4,0)
 ;;=4^H35.013
 ;;^UTILITY(U,$J,358.3,12888,2)
 ;;=^5005584
 ;;^UTILITY(U,$J,358.3,12889,0)
 ;;=H35.011^^51^623^38
 ;;^UTILITY(U,$J,358.3,12889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12889,1,3,0)
 ;;=3^Changes in Retinal Vascular Appearance,OD
 ;;^UTILITY(U,$J,358.3,12889,1,4,0)
 ;;=4^H35.011
 ;;^UTILITY(U,$J,358.3,12889,2)
 ;;=^5005582
 ;;^UTILITY(U,$J,358.3,12890,0)
 ;;=H35.012^^51^623^39
 ;;^UTILITY(U,$J,358.3,12890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12890,1,3,0)
 ;;=3^Changes in Retinal Vascular Appearance,OS
 ;;^UTILITY(U,$J,358.3,12890,1,4,0)
 ;;=4^H35.012
 ;;^UTILITY(U,$J,358.3,12890,2)
 ;;=^5005583
 ;;^UTILITY(U,$J,358.3,12891,0)
 ;;=H35.023^^51^623^43
 ;;^UTILITY(U,$J,358.3,12891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12891,1,3,0)
 ;;=3^Exudative Retinopathy,OU
 ;;^UTILITY(U,$J,358.3,12891,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,12891,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,12892,0)
 ;;=H35.021^^51^623^41
 ;;^UTILITY(U,$J,358.3,12892,1,0)
 ;;=^358.31IA^4^2
